Trial · NCT07881432
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change from Baseline in Body Weight | Baseline, Week 100 | |
| Secondary | Change from Baseline in Waist Circumference | Baseline, Week 100 | |
| Secondary | Percent Change from Baseline in Triglycerides | Baseline, Week 100 | |
| Secondary | Change from Baseline in Systolic Blood Pressure | Baseline, Week 100 | |
| Secondary | Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) | Baseline, Week 100 | |
| Secondary | Percent Change from Baseline in Total Body Fat Mass | Baseline, Week 100 | |
| Secondary | Change from Baseline in Body Mass Index (BMI) | Baseline, Week 100 | |
| Secondary | Change from Baseline in Hemoglobin A1c (HbA1c) | Baseline, Week 100 | |
| Secondary | Percent Change from Baseline in Fasting Insulin | Baseline, Week 100 | |
| Secondary | Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) | Baseline, Week 100 | |
| Secondary | Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) Score | Baseline, Week 100 | |
| Secondary | Change from Baseline in EQ-5D-5L Score | Baseline, Week 100 | |
| Secondary | Change from Baseline in Eating Behaviors and Attitudes Questionnaire (EBAQ) Score | Baseline, Week 100 | |
| Secondary | Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight | Baseline, Week 100 | |
| Secondary | Percentage of Participants with a Change in Medication Use | Baseline through Week 100 | |
| Secondary | Percentage of Participants who Develop Type 2 Diabetes | Baseline through Week 100 | |
| Secondary | Overall Functional Assessment of Chronic Illness Therapy, Item GP5 (FACT-GP5) Score | Week 100 | |
| Secondary | Pharmacokinetics (PK): Maximum Concentration of Eloralintide at Steady State (Cmax,ss) | Baseline through Week 100 | |
| Secondary | PK: Area Under the Concentration Versus Time Curve of Eloralintide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss) | Baseline through Week 100 | |
| Secondary | PK: Maximum Concentration of Tirzepatide at Steady State (Cmax,ss) | Baseline through Week 100 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07881432/registered